NCT07177716View on ClinicalTrials.gov

Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

LB1410

LB1410 (IV, Q2W for up to 2 years)

BIOLOGICAL

LB4330

LB4330 (IV, Q2W for 4 cycles)

DRUG

Lenvatinib

lenvatinib (oral, once daily for up to 2 years)

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

L & L Bio Co., Ltd., Ningbo, China

INDUSTRY